"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 3 | 4 |
| 2001 | 2 | 5 | 7 |
| 2002 | 3 | 3 | 6 |
| 2003 | 2 | 4 | 6 |
| 2004 | 5 | 7 | 12 |
| 2005 | 3 | 2 | 5 |
| 2006 | 5 | 2 | 7 |
| 2007 | 4 | 1 | 5 |
| 2008 | 7 | 5 | 12 |
| 2009 | 4 | 2 | 6 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 5 | 10 |
| 2012 | 8 | 7 | 15 |
| 2013 | 8 | 10 | 18 |
| 2014 | 9 | 10 | 19 |
| 2015 | 9 | 18 | 27 |
| 2016 | 20 | 2 | 22 |
| 2017 | 21 | 6 | 27 |
| 2018 | 32 | 16 | 48 |
| 2019 | 31 | 18 | 49 |
| 2020 | 21 | 27 | 48 |
| 2021 | 20 | 22 | 42 |
| 2022 | 4 | 29 | 33 |
| 2023 | 4 | 34 | 38 |
| 2024 | 23 | 27 | 50 |
| 2025 | 17 | 7 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis. J Natl Cancer Inst. 2025 Nov 01; 117(11):2388-2393.
-
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024. Cancer. 2025 Sep 01; 131(17):e70060.
-
Progressive Immunotherapy-Related Mucocutaneous Eruption: A Mimicker of SJS-TEN. Am J Dermatopathol. 2025 Oct 01; 47(10):750-753.
-
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1?
-
Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease. Clin Cancer Res. 2025 Jul 01; 31(13):2556-2564.
-
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025 Nov; 20(11):1615-1625.
-
Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates. Nat Biomed Eng. 2025 Oct; 9(10):1719-1739.
-
Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Oncotarget. 2025 Jun 10; 16:427-442.
-
YTHDFs as radiotherapy checkpoints in tumor immunity. J Exp Med. 2025 Aug 04; 222(8).
-
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference. Oncoimmunology. 2025 Dec; 14(1):2507856.
People
People who have written about this concept.
Explore
_
Similar Concepts
Similar concepts derived from published works.
_
Top Journals
Top journals in which articles about this concept have been published.